Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2016, Article ID 1279042, 19 pages
http://dx.doi.org/10.1155/2016/1279042
Review Article

Marijuana Compounds: A Nonconventional Approach to Parkinson’s Disease Therapy

Touro College of Pharmacy, 230 West 125th Street, Room 530, New York, NY 10027, USA

Received 8 June 2016; Revised 29 September 2016; Accepted 10 October 2016

Academic Editor: Jan Aasly

Copyright © 2016 Mariana Babayeva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. M. Borgelt, K. L. Franson, A. M. Nussbaum, and G. S. Wang, “The pharmacologic and clinical effects of medical cannabis,” Pharmacotherapy, vol. 33, no. 2, pp. 195–209, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. M. A. ElSohly and D. Slade, “Chemical constituents of marijuana: the complex mixture of natural cannabinoids,” Life Sciences, vol. 78, no. 5, pp. 539–548, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. E. B. Russo, “Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects,” British Journal of Pharmacology, vol. 163, no. 7, pp. 1344–1364, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. E. J. Rahn and A. G. Hohmann, “Cannabinoids as Pharmacotherapies for neuropathic pain: from the bench to the bedside,” Neurotherapeutics, vol. 6, no. 4, pp. 713–737, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. A. W. Zuardi, “Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action,” Revista Brasileira de Psiquiatria, vol. 30, no. 3, pp. 271–280, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. F. M. Leweke, D. Piomelli, F. Pahlisch et al., “Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia,” Translational Psychiatry, vol. 2, no. 3, article e94, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. DEA (Drug Enforcement Administration), Drug Fact Sheet: Marijuana, http://www.dea.gov/druginfo/drug_data_sheets/Marijuana.pdf.
  8. ONDCP (Office of National Drug Control Policy), Marijuana Resource Center: State Laws Related to Marijuana, https://www.whitehouse.gov/ondcp/state-laws-related-to-marijuana.
  9. Y. Park, “Georgia Regents University. Epidiolex and Drug Resistant Epilepsy in Children (CBD),” In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). NLM Identifier: NCT02397863, https://clinicaltrials.gov/ct2/show/NCT02397863.
  10. W. Notcutt, R. Langford, P. Davies, S. Ratcliffe, and R. Potts, “A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex (nabiximols),” Multiple Sclerosis Journal, vol. 18, no. 2, pp. 219–228, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Novotna, J. Mares, S. Ratcliffe et al., “A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis,” European Journal of Neurology, vol. 18, no. 9, pp. 1122–1131, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Grotenhermen and K. Müller-Vahl, “The therapeutic potential of cannabis and cannabinoids,” Deutsches Arzteblatt International, vol. 109, no. 29-30, pp. 495–501, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Scuderi, D. De Filippis, T. Iuvone, A. Blasio, A. Steardo, and G. Esposito, “Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders,” Phytotherapy Research, vol. 23, no. 5, pp. 597–602, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Iuvone, G. Esposito, D. De Filippis, C. Scuderi, and L. Steardo, “Cannabidiol: a promising drug for neurodegenerative disorders?” CNS Neuroscience and Therapeutics, vol. 15, no. 1, pp. 65–75, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. J. Hill, C. M. Williams, B. J. Whalley, and G. J. Stephens, “Phytocannabinoids as novel therapeutic agents in CNS disorders,” Pharmacology and Therapeutics, vol. 133, no. 1, pp. 79–97, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Fusar-Poli, J. A. Crippa, S. Bhattacharyya et al., “Distinct effects of Δ9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing,” Archives of General Psychiatry Journal, vol. 66, no. 1, pp. 95–105, 2009. View at Publisher · View at Google Scholar
  17. D. T. Malone, M. N. Hill, and T. Rubino, “Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models,” British Journal of Pharmacology, vol. 160, no. 3, pp. 511–522, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Gerra, A. Zaimovic, M. L. Gerra et al., “Pharmacology and toxicology of cannabis derivatives and endocannabinoid agonists,” Recent Patents on CNS Drug Discovery, vol. 5, no. 1, pp. 46–52, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. T. H. Moore, S. Zammit, A. Lingford-Hughes et al., “Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review,” The Lancet, vol. 370, no. 9584, pp. 319–328, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. M. G. Bossong and R. J. M. Niesink, “Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia,” Progress in Neurobiology, vol. 92, no. 3, pp. 370–385, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Schneider, “Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure,” Addiction Biology, vol. 13, no. 2, pp. 253–263, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Grotenhermen, “The toxicology of cannabis and cannabis prohibition,” Chemistry & Biodiversity, vol. 4, no. 8, pp. 1744–1769, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. F. R. de Fonseca, I. del Arco, F. J. Bermudez-Silva, A. Bilbao, A. Cippitelli, and M. Navarro, “The endocannabinoid system: physiology and pharmacology,” Alcohol and Alcoholism, vol. 40, no. 1, pp. 2–14, 2005. View at Google Scholar
  24. P. Pacher, S. Bátkai, and G. Kunos, “The endocannabinoid system as an emerging target of pharmacotherapy,” Pharmacological Reviews, vol. 58, no. 3, pp. 389–462, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Morera-Herreras, C. Miguelez, A. Aristieta, J. A. Ruiz-Ortega, and L. Ugedo, “Endocannabinoid modulation of dopaminergic motor circuits,” Frontiers in Pharmacology, vol. 3, article 110, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. A. El Manira and A. Kyriakatos, “The role of endocannabinoid signaling in motor control,” Physiology, vol. 25, no. 4, pp. 230–238, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Fernández-Ruiz and S. González, “Cannabinoid control of motor function at the Basal Ganglia,” Handbook of Experimental Pharmacology, vol. 168, pp. 479–507, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Xu, K. D. Kochanek, and S. L. Murphy, “National vital statistics reports deaths: final data for 2007,” Statistics, vol. 58, no. 3, p. 135, 2010. View at Google Scholar
  29. T. Pringsheim, N. Jette, A. Frolkis, and T. D. L. Steeves, “The prevalence of Parkinson's disease: a systematic review and meta-analysis,” Movement Disorders, vol. 29, no. 13, pp. 1583–1590, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. E. R. Dorsey, R. Constantinescu, J. P. Thompson et al., “Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030,” Neurology, vol. 68, no. 5, pp. 384–386, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. L. C. S. Tan, “Epidemiology of parkinson's disease,” Neurology Asia, vol. 18, no. 3, pp. 231–238, 2013. View at Google Scholar · View at Scopus
  32. A. Galvan and T. Wichmann, “Pathophysiology of Parkinsonism,” Clinical Neurophysiology, vol. 119, no. 7, pp. 1459–1474, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. L. C. Kwan and T. L. Whitehill, “Perception of speech by individuals with Parkinson's disease: a review,” Parkinson's Disease, vol. 2011, Article ID 389767, 11 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Thomas and M. F. Beal, “Parkinson's disease,” Human Molecular Genetics, vol. 16, no. 2, pp. R183–R194, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. G. E. Alexander, “Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder,” Dialogues in Clinical Neuroscience, vol. 6, no. 3, pp. 259–280, 2004. View at Google Scholar · View at Scopus
  36. W. Dauer and S. Przedborski, “Parkinson's disease: mechanisms and models,” Neuron, vol. 39, no. 6, pp. 889–909, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. M. C. Rodriguez-Oroz, M. Jahanshahi, P. Krack et al., “Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms,” The Lancet Neurology, vol. 8, no. 12, pp. 1128–1139, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Patel and F. Chang, “Parkinson's disease guidelines for pharmacists,” Canadian Pharmacists Journal, vol. 147, no. 3, pp. 161–170, 2014. View at Publisher · View at Google Scholar
  39. K. R. Chaudhuri, D. G. Healy, and A. H. V. Schapira, “Non-motor symptoms of Parkinson's disease: diagnosis and management,” The Lancet Neurology, vol. 5, no. 3, pp. 235–245, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. B. Müller, J. Assmus, K. Herlofson, J. P. Larsen, and O.-B. Tysnes, “Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson's disease,” Parkinsonism and Related Disorders, vol. 19, no. 11, pp. 1027–1032, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Latoo, M. Mistry, and F. J. Dunne, “Often overlooked neuropsychiatric syndromes in Parkinson's disease,” British Journal of Medical Practitioners, vol. 6, no. 1, pp. 23–30, 2013. View at Google Scholar · View at Scopus
  42. F. Stocchi, G. Abbruzzese, R. Ceravolo et al., “Prevalence of fatigue in Parkinson disease and its clinical correlates,” Neurology, vol. 83, no. 3, pp. 215–220, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. D. C. Velseboer, R. J. de Haan, W. Wieling, D. S. Goldstein, and R. M. A. de Bie, “Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis,” Parkinsonism and Related Disorders, vol. 17, no. 10, pp. 724–729, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. B. Connolly and S. H. Fox, “Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease,” Neurotherapeutics, vol. 11, no. 1, pp. 78–91, 2014. View at Publisher · View at Google Scholar
  45. P. Huot, S. H. Fox, and J. M. Brotchie, “Monoamine reuptake inhibitors in Parkinson's disease,” Parkinson's Disease, vol. 2015, Article ID 609428, 71 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Gasparini, T. Di Paolo, and B. Gomez-Mancilla, “Metabotropic glutamate receptors for Parkinson's disease therapy,” Parkinson's Disease, vol. 2013, Article ID 196028, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. C. G. Goetz and G. Pal, “Initial management of Parkinson's disease,” British Medical Journal, vol. 349, Article ID 6258, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Lees, “Alternatives to levodopa in the initial treatment of early Parkinson's disease,” Drugs and Aging, vol. 22, no. 9, pp. 731–740, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Katzenschlager, C. Sampaio, J. Costa, and A. Lees, “Anticholinergics for symptomatic management of Parkinson's disease,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD003735, 2003. View at Google Scholar · View at Scopus
  50. S. Maranis, S. Tsouli, and S. Konitsiotis, “Treatment of motor symptoms in advanced Parkinson's disease: a practical approach,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 35, no. 8, pp. 1795–1807, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. R. Heumann, R. Moratalla, M. T. Herrero et al., “Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions,” Journal of Neurochemistry, vol. 130, no. 4, pp. 472–489, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Politis, K. Wu, C. Loane et al., “Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients,” The Journal of Clinical Investigation, vol. 124, no. 3, pp. 1340–1349, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. G. Porras, P. De Deurwaerdere, Q. Li et al., “L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum,” Scientific Reports, vol. 4, article 3730, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. J. J. Chen, D. M. Swope, and K. Dashtipour, “Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's Disease,” Clinical Therapeutics, vol. 29, no. 9, pp. 1825–1849, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Lecht, S. Haroutiunian, A. Hoffman, and P. Lazarovici, “Rasagiline—a novel MAO B inhibitor in Parkinson's disease therapy,” Therapeutics and Clinical Risk Management, vol. 3, no. 3, pp. 467–474, 2007. View at Google Scholar · View at Scopus
  56. R. Pahwa, S. A. Factor, K. E. Lyons et al., “Practice parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology,” Neurology, vol. 66, no. 7, pp. 983–995, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. F. Stocchi and J. M. Rabey, “Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease,” European Journal of Neurology, vol. 18, no. 12, pp. 1373–1378, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. O. Rascol, D. J. Brooks, E. Melamed et al., “Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial,” The Lancet Neurology, vol. 365, pp. 947–954, 2005. View at Google Scholar
  59. E. Tolosa and M. B. Stern, “Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease,” European Journal of Neurology, vol. 19, no. 2, pp. 258–264, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. O. Rascol, D. J. Brooks, A. D. Korczyn, P. P. De Deyn, C. E. Clarke, and A. E. Lang, “A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa,” The New England Journal of Medicine, vol. 342, no. 20, pp. 1484–1491, 2000. View at Publisher · View at Google Scholar · View at Scopus
  61. Parkinson Study Group, “Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group,” The Journal of the American Medical Association, vol. 284, no. 15, pp. 1931–1938, 2000. View at Publisher · View at Google Scholar
  62. S. Perez-Lloret, M. V. Rey, P. L. Ratti, and O. Rascol, “Rotigotine transdermal patch for the treatment of Parkinson's disease,” Fundamental and Clinical Pharmacology, vol. 27, no. 1, pp. 81–95, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. J.-P. Elshoff, W. Cawello, J.-O. Andreas, F.-X. Mathy, and M. Braun, “An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome,” Drugs, vol. 75, no. 5, pp. 487–501, 2015. View at Publisher · View at Google Scholar · View at Scopus
  64. D. Deleu, Y. Hanssens, and M. G. Northway, “Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease,” Drugs and Aging, vol. 21, no. 11, pp. 687–709, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. I. Lotan, T. A. Treves, Y. Roditi, and R. Djaldetti, “Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease,” Clinical Neuropharmacology, vol. 37, no. 2, pp. 41–44, 2014. View at Google Scholar
  66. T. A. Finseth, J. L. Hedeman, R. P. Brown, K. I. Johnson, M. S. Binder, and B. M. Kluger, “Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson's disease patients in Colorado,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 874849, 6 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  67. A. W. Zuardi, J. A. S. Crippa, J. E. C. Hallak et al., “Cannabidiol for the treatment of psychosis in Parkinson's disease,” Journal of Psychopharmacology, vol. 23, no. 8, pp. 979–983, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. M. H. N. Chagas, A. W. Zuardi, V. Tumas et al., “Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial,” Journal of Psychopharmacology, vol. 28, no. 11, pp. 1088–1092, 2014. View at Publisher · View at Google Scholar · View at Scopus
  69. M. H. N. Chagas, A. L. Eckeli, A. W. Zuardi et al., “Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series,” Journal of Clinical Pharmacy and Therapeutics, vol. 39, no. 5, pp. 564–566, 2014. View at Publisher · View at Google Scholar · View at Scopus
  70. C. García, C. Palomo-Garo, M. García-Arencibia, J. A. Ramos, R. G. Pertwee, and J. Fernández-Ruiz, “Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson's disease,” British Journal of Pharmacology, vol. 163, no. 7, pp. 1495–1506, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Shen and S. A. Thayer, “Δ9-Tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture,” Molecular Pharmacology, vol. 55, no. 1, pp. 8–13, 1999. View at Google Scholar · View at Scopus
  72. R. Murase, R. Kawamura, E. Singer et al., “Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer,” British Journal of Pharmacology, vol. 171, no. 19, pp. 4464–4477, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. O. Devinsky, M. R. Cilio, H. Cross et al., “Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders,” Epilepsia, vol. 55, no. 6, pp. 791–802, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Babayeva, M. Fuzailov, P. Rozenfeld, and P. Basu, “Marijuana compounds: a non-conventional therapeutic approach to epilepsy in children,” Journal of Addiction Neuropharmacology, vol. 1, pp. 2–36, 2014. View at Google Scholar
  75. J. L. Croxford, “Therapeutic potential of cannabinoids in CNS disease,” CNS Drugs, vol. 17, no. 3, pp. 179–202, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. J. Fernández-Ruiz, O. Sagredo, M. R. Pazos et al., “Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?” British Journal of Clinical Pharmacology, vol. 75, no. 2, pp. 323–333, 2013. View at Publisher · View at Google Scholar · View at Scopus
  77. Y. Hashimotodani, T. Ohno-Shosaku, M. Watanabe, and M. Kano, “Roles of phospholipase Cβ and NMDA receptor in activity-dependent endocannabinoid release,” The Journal of Physiology, vol. 584, no. 2, pp. 373–380, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. Z. Hegyi, K. Holló, G. Kis, K. Mackie, and M. Antal, “Differential distribution of diacylglycerol lipase-alpha and N-acylphosphatidylethanolamine-specific phospholipase d immunoreactivity in the superficial spinal dorsal horn of rats,” Glia, vol. 60, no. 9, pp. 1316–1329, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. P. G. Fine and M. J. Rosenfeld, “The endocannabinoid system, cannabinoids, and pain,” Rambam Maimonides Medical Journal, vol. 4, no. 4, Article ID e0022, 2013. View at Publisher · View at Google Scholar
  80. E. M. Marco, S. Y. Romero-Zerbo, M.-P. Viveros, and F. J. Bermudez-Silva, “The role of the endocannabinoid system in eating disorders: pharmacological implications,” Behavioural Pharmacology, vol. 23, no. 5-6, pp. 526–536, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. C. R. Hiley, “Endocannabinoids and the heart,” Journal of Cardiovascular Pharmacology, vol. 53, no. 4, pp. 267–276, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. R. G. Pertwee, “The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: Δ 9-tetrahydrocannabinol, cannabidiol and Δ 9-tetrahydrocannabivarin,” British Journal of Pharmacology, vol. 153, no. 2, pp. 199–215, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. J.-Y. Xu and C. Chen, “Endocannabinoids in synaptic plasticity and neuroprotection,” Neuroscientist, vol. 21, no. 2, pp. 152–168, 2015. View at Publisher · View at Google Scholar · View at Scopus
  84. V. L. Hegde, M. Nagarkatti, and P. S. Nagarkatti, “Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties,” European Journal of Immunology, vol. 40, no. 12, pp. 3358–3371, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. S. Pérez-Rial, M. S. García-Gutiérrez, J. A. Molina et al., “Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors,” Neurobiology of Aging, vol. 32, no. 4, pp. 631–645, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. D. Piomelli, “The molecular logic of endocannabinoid signalling,” Nature Reviews Neuroscience, vol. 4, no. 11, pp. 873–884, 2003. View at Publisher · View at Google Scholar · View at Scopus
  87. L. A. Matsuda, S. J. Lolait, M. J. Brownstein, A. C. Young, and T. I. Bonner, “Structure of a cannabinoid receptor and functional expression of the cloned cDNA,” Nature, vol. 346, no. 6284, pp. 561–564, 1990. View at Publisher · View at Google Scholar · View at Scopus
  88. M. Herkenham, A. B. Lynn, M. D. Little et al., “Cannabinoid receptor localization in brain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 5, pp. 1932–1936, 1990. View at Publisher · View at Google Scholar · View at Scopus
  89. I. Ivanov, P. Borchert, and B. Hinz, “A simple method for simultaneous determination of N-arachidonoylethanolamine, N-oleoylethanolamine, N-palmitoylethanolamine and 2-arachidonoylglycerol in human cells,” Analytical and Bioanalytical Chemistry, vol. 407, no. 6, pp. 1781–1787, 2015. View at Publisher · View at Google Scholar · View at Scopus
  90. R. G. Pertwee, A. C. Howlett, M. E. Abood et al., “International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB1 and CB2,” Pharmacological Reviews, vol. 62, no. 4, pp. 588–631, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. N. T. Snider, V. J. Walker, and P. F. Hollenberg, “Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications,” Pharmacological Reviews, vol. 62, no. 1, pp. 136–154, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. M. W. Buczynski and L. H. Parsons, “Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls,” British Journal of Pharmacology, vol. 160, no. 3, pp. 423–442, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. C. C. Felder, A. Nielsen, E. M. Briley et al., “Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat,” FEBS Letters, vol. 393, no. 2-3, pp. 231–235, 1996. View at Publisher · View at Google Scholar · View at Scopus
  94. T. Sugiura, S. Kondo, S. Kishimoto et al., “Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells,” Journal of Biological Chemistry, vol. 275, no. 1, pp. 605–612, 2000. View at Publisher · View at Google Scholar · View at Scopus
  95. T. Bisogno, F. Berrendero, G. Ambrosino et al., “Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function,” Biochemical and Biophysical Research Communications, vol. 256, no. 2, pp. 377–380, 1999. View at Google Scholar
  96. R. Mechoulam, S. Ben-Shabat, L. Hanus et al., “Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors,” Biochemical Pharmacology, vol. 50, no. 1, pp. 83–90, 1995. View at Publisher · View at Google Scholar · View at Scopus
  97. W. Gonsiorek, C. Lunn, X. Fan, S. Narula, D. Lundell, and R. W. Hipkin, “Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide,” Molecular Pharmacology, vol. 57, no. 5, pp. 1045–1050, 2000. View at Google Scholar · View at Scopus
  98. V. Di Marzo, F. Berrendero, T. Bisogno et al., “Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of Δ9- tetrahydrocannabinol-tolerant rats,” Journal of Neurochemistry, vol. 74, no. 4, pp. 1627–1635, 2000. View at Publisher · View at Google Scholar · View at Scopus
  99. V. Di Marzo, M. P. Hill, T. Bisogno, A. R. Crossman, and J. M. Brotchie, “Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease,” FASEB Journal, vol. 14, no. 10, pp. 1432–1438, 2000. View at Publisher · View at Google Scholar · View at Scopus
  100. G. Palermo, I. Bauer, P. Campomanes et al., “Keys to lipid selection in fatty acid amide hydrolase catalysis: structural flexibility, gating residues and multiple binding pockets,” PLoS Computational Biology, vol. 11, no. 6, article e1004231, 2015. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Giuffrida, L. H. Parsons, T. M. Kerr, F. Rodríguez De Fonseca, M. Navarro, and D. Piomelli, “Dopamine activation of endogenous cannabinoid signaling in dorsal striatum,” Nature Neuroscience, vol. 2, no. 4, pp. 358–363, 1999. View at Publisher · View at Google Scholar · View at Scopus
  102. L. De Petrocellis, M. G. Cascio, and V. Di Marzo, “The endocannabinoid system: a general view and latest additions,” British Journal of Pharmacology, vol. 141, no. 5, pp. 765–774, 2004. View at Publisher · View at Google Scholar · View at Scopus
  103. B. S. Basavarajappa, “Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity,” Current Neuropharmacology, vol. 5, no. 2, pp. 81–97, 2007. View at Publisher · View at Google Scholar · View at Scopus
  104. I. G. Karniol and E. A. Carlini, “Pharmacological interaction between cannabidiol and δ9-tetrahydrocannabinol,” Psychopharmacologia, vol. 33, no. 1, pp. 53–70, 1973. View at Publisher · View at Google Scholar · View at Scopus
  105. R. Mechoulam and Y. Shvo, “Hashish—I: the structure of cannabidiol,” Tetrahedron, vol. 19, pp. 2073–2078, 1963. View at Google Scholar
  106. V. Di Marzo and A. Fontana, “Anandamide, an endogenous cannabinomimetic eicosanoid: ‘killing two birds with one stone’,” Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 53, no. 1, pp. 1–11, 1995. View at Publisher · View at Google Scholar · View at Scopus
  107. H. J. Groenewegen, “The basal ganglia and motor control,” Neural Plasticity, vol. 10, no. 1-2, pp. 107–120, 2003. View at Publisher · View at Google Scholar · View at Scopus
  108. P. Calabresi, B. Picconi, A. Tozzi, V. Ghiglieri, and M. Di Filippo, “Direct and indirect pathways of basal ganglia: a critical reappraisal,” Nature Neuroscience, vol. 17, no. 8, pp. 1022–1030, 2014. View at Publisher · View at Google Scholar · View at Scopus
  109. J. Fernández-Ruiz, “The endocannabinoid system as a target for the treatment of motor dysfunction,” British Journal of Pharmacology, vol. 156, no. 7, pp. 1029–1040, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. B. D. Heifets and P. E. Castillo, “Endocannabinoid signaling and long-term synaptic plasticity,” Annual Review of Physiology, vol. 71, pp. 283–306, 2009. View at Publisher · View at Google Scholar · View at Scopus
  111. E. Bezard, J. M. Brotchie, and C. E. Gross, “Pathophysiology of levodopa-induced dyskinesia: potential for new therapies,” Nature Reviews Neuroscience, vol. 2, no. 8, pp. 577–588, 2001. View at Publisher · View at Google Scholar · View at Scopus
  112. S. V. More and D.-K. Choi, “Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection,” Molecular Neurodegeneration, vol. 10, no. 1, article 17, 2015. View at Publisher · View at Google Scholar · View at Scopus
  113. M. García-Arencibia, C. García, and J. Fernández-Ruiz, “Cannabinoids and Parkinson's disease,” CNS and Neurological Disorders—Drug Targets, vol. 8, no. 6, pp. 432–439, 2009. View at Publisher · View at Google Scholar · View at Scopus
  114. J. M. Brotchie, “CB1 cannabinoid receptor signalling in Parkinson's disease,” Current Opinion in Pharmacology, vol. 3, no. 1, pp. 54–61, 2003. View at Publisher · View at Google Scholar · View at Scopus
  115. M. van der Stelt and V. Di Marzo, “The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders,” European Journal of Pharmacology, vol. 480, no. 1–3, pp. 133–150, 2003. View at Publisher · View at Google Scholar · View at Scopus
  116. E. Benarroch, “Endocannabinoids in basal ganglia circuits: implications for Parkinson disease,” Neurology, vol. 69, no. 3, pp. 306–309, 2007. View at Publisher · View at Google Scholar · View at Scopus
  117. F. R. Fusco, A. Martorana, C. Giampà et al., “Immunolocalization of CB1 receptor in rat striatal neurons: A Confocal Microscopy Study,” Synapse, vol. 53, no. 3, pp. 159–167, 2004. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Di Filippo, B. Picconi, A. Tozzi, V. Ghiglieri, A. Rossi, and P. Calabresi, “The endocannabinoid system in Pakinson's disease,” Current Pharmaceutical Design, vol. 14, no. 23, pp. 2337–2346, 2008. View at Publisher · View at Google Scholar · View at Scopus
  119. I. Lastres-Becker, M. Cebeira, M. L. De Ceballos et al., “Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets,” European Journal of Neuroscience, vol. 14, no. 11, pp. 1827–1832, 2001. View at Publisher · View at Google Scholar · View at Scopus
  120. I. Lastres-Becker, F. Fezza, M. Cebeira et al., “Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease,” NeuroReport, vol. 12, no. 10, pp. 2125–2129, 2001. View at Publisher · View at Google Scholar · View at Scopus
  121. T. M. Dawson and V. L. Dawson, “Rare genetic mutations shed light on the pathogenesis of Parkinson disease,” The Journal of Clinical Investigation, vol. 111, no. 2, pp. 145–151, 2003. View at Publisher · View at Google Scholar · View at Scopus
  122. S. González, M. A. Mena, I. Lastres-Becker et al., “Cannabinoid CB1 receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice,” Brain Research, vol. 1046, no. 1-2, pp. 195–206, 2005. View at Publisher · View at Google Scholar · View at Scopus
  123. R. I. Wilson and R. A. Nicoll, “Endocannabinoid signaling in the brain,” Science, vol. 296, no. 5568, pp. 678–682, 2002. View at Publisher · View at Google Scholar · View at Scopus
  124. J. P. Meschler, T. J. Conley, and A. C. Howlett, “Cannabinoid and dopamine interaction in rodent brain: effects on locomotor activity,” Pharmacology Biochemistry and Behavior, vol. 67, no. 3, pp. 567–573, 2000. View at Publisher · View at Google Scholar · View at Scopus
  125. J. P. Meschler, A. C. Howlett, and B. K. Madras, “Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates,” Psychopharmacology, vol. 156, no. 1, pp. 79–85, 2001. View at Publisher · View at Google Scholar · View at Scopus
  126. L. A. Batista, P. H. Gobira, T. G. Viana, D. C. Aguiar, and F. A. Moreira, “Inhibition of endocannabinoid neuronal uptake and hydrolysis as strategies for developing anxiolytic drugs,” Behavioural Pharmacology, vol. 25, no. 5-6, pp. 425–433, 2014. View at Publisher · View at Google Scholar · View at Scopus
  127. É. Mezey, Z. E. Tóth, D. N. Cortright et al., “Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1- like immunoreactivity, in the central nervous system of the rat and human,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 7, pp. 3655–3660, 2000. View at Publisher · View at Google Scholar · View at Scopus
  128. E. Palazzo, F. Rossi, and S. Maione, “Role of TRPV1 receptors in descending modulation of pain,” Molecular and Cellular Endocrinology, vol. 286, no. 1-2, supplement 1, pp. S79–S83, 2008. View at Publisher · View at Google Scholar · View at Scopus
  129. E. de Lago, R. de Miguel, I. Lastres-Becker, J. A. Ramos, and J. Fernández-Ruiz, “Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence,” Brain Research, vol. 1007, no. 1-2, pp. 152–159, 2004. View at Publisher · View at Google Scholar · View at Scopus
  130. T. dos Anjos-Garcia, F. Ullah, L. L. Falconi-Sobrinho, and N. C. Coimbra, “CB1 cannabinoid receptor-mediated anandamide signalling reduces the defensive behaviour evoked through GABAA receptor blockade in the dorsomedial division of the ventromedial hypothalamus,” Neuropharmacology, vol. 113, pp. 156–166, 2016. View at Publisher · View at Google Scholar
  131. E. Lizanecz, Z. Bagi, E. T. Pásztor et al., “Phosphorylation-dependent desensitization by anandamide of vanilloid receptor-1 (TRPV1) function in rat skeletal muscle arterioles and in Chinese hamster ovary cells expressing TRPV1,” Molecular Pharmacology, vol. 69, no. 3, pp. 1015–1023, 2006. View at Publisher · View at Google Scholar · View at Scopus
  132. A. V. Kravitz, B. S. Freeze, P. R. L. Parker et al., “Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry,” Nature, vol. 466, no. 7306, pp. 622–626, 2010. View at Publisher · View at Google Scholar · View at Scopus
  133. A. C. Kreitzer and R. C. Malenka, “Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models,” Nature, vol. 445, no. 7128, pp. 643–647, 2007. View at Publisher · View at Google Scholar · View at Scopus
  134. O. Sagredo, M. R. Pazos, V. Satta, J. A. Ramos, R. G. Pertwee, and J. Fernández-Ruiz, “Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease,” Journal of Neuroscience Research, vol. 89, no. 9, pp. 1509–1518, 2011. View at Publisher · View at Google Scholar · View at Scopus
  135. D. E. Moss, S. B. McMaster, and J. Rogers, “Tetrahydrocannabinol potentiates reserpine-induced hypokinesia,” Pharmacology, Biochemistry and Behavior, vol. 15, no. 5, pp. 779–783, 1981. View at Publisher · View at Google Scholar · View at Scopus
  136. M. Van Der Stelt, S. H. Fox, M. Hill et al., “A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease,” FASEB Journal, vol. 19, no. 9, pp. 1140–1142, 2005. View at Publisher · View at Google Scholar · View at Scopus
  137. T. Bisogno, F. Berrendero, G. Ambrosino et al., “Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function,” Biochemical and Biophysical Research Communications, vol. 256, no. 2, pp. 377–380, 1999. View at Publisher · View at Google Scholar · View at Scopus
  138. M. C. Sañudo-Peña, K. Tsou, and J. M. Walker, “Motor actions of cannabinoids in the basal ganglia output nuclei,” Life Sciences, vol. 65, no. 6-7, pp. 703–713, 1999. View at Publisher · View at Google Scholar · View at Scopus
  139. I. Lastres-Becker, H. H. Hansen, F. Berrendero et al., “Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease,” Synapse, vol. 44, no. 1, pp. 23–35, 2002. View at Publisher · View at Google Scholar · View at Scopus
  140. M. Glass, M. Dragunow, and R. L. Faull, “The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease,” Neuroscience, vol. 97, no. 3, pp. 505–519, 2000. View at Publisher · View at Google Scholar
  141. K. Van Laere, C. Casteels, S. Lunskens et al., “Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo,” Neurobiology of Aging, vol. 33, no. 3, pp. 620.e1–620.e8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  142. E. M. Romero, B. Fernández, O. Sagredo et al., “Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats,” Developmental Brain Research, vol. 136, no. 2, pp. 85–92, 2002. View at Publisher · View at Google Scholar · View at Scopus
  143. L. E. Long, R. Chesworth, X.-F. Huang, I. S. McGregor, J. C. Arnold, and T. Karl, “A behavioural comparison of acute and chronic 9- tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice,” International Journal of Neuropsychopharmacology, vol. 13, no. 7, pp. 861–876, 2010. View at Publisher · View at Google Scholar · View at Scopus
  144. W. R. Prescott, L. H. Gold, and B. R. Martin, “Evidence for separate neuronal mechanisms for the discriminative stimulus and catalepsy induced by Δ9-THC in the rat,” Psychopharmacology, vol. 107, no. 1, pp. 117–124, 1992. View at Publisher · View at Google Scholar · View at Scopus
  145. J. N. Crawley, R. L. Corwin, J. K. Robinson, C. C. Felder, W. A. Devane, and J. Axelrod, “Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents,” Pharmacology, Biochemistry and Behavior, vol. 46, no. 4, pp. 967–972, 1993. View at Publisher · View at Google Scholar · View at Scopus
  146. J. Romero, R. de Miguel, E. García-Palomero, J. J. Fernández-Ruiz, and J. A. Ramos, “Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function,” Brain Research, vol. 694, no. 1-2, pp. 223–232, 1995. View at Publisher · View at Google Scholar · View at Scopus
  147. J. Romero, L. Garcia, M. Cebeira, D. Zadrozny, J. J. Fernández-Ruiz, and J. A. Ramos, “The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons,” Life Sciences, vol. 56, no. 23-24, pp. 2033–2040, 1995. View at Publisher · View at Google Scholar · View at Scopus
  148. L. A. Anderson, J. J. Anderson, T. N. Chase, and J. R. Walters, “The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway,” Brain Research, vol. 691, no. 1-2, pp. 106–114, 1995. View at Publisher · View at Google Scholar · View at Scopus
  149. J. Fernández-Ruiz, I. Lastres-Becker, A. Cabranes, S. González, and J. A. Ramos, “Endocannabinoids and basal ganglia functionality,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 66, no. 2-3, pp. 257–267, 2002. View at Publisher · View at Google Scholar · View at Scopus
  150. M. Herkenham, A. B. Lynn, M. Ross Johnson, L. S. Melvin, B. R. De Costa, and K. C. Rice, “Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study,” Journal of Neuroscience, vol. 11, no. 2, pp. 563–583, 1991. View at Google Scholar · View at Scopus
  151. A. G. Hohmann and M. Herkenham, “Localization of cannabinoid CB1 receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study,” Synapse, vol. 37, no. 1, pp. 71–80, 2000. View at Publisher · View at Google Scholar · View at Scopus
  152. J. Romero, I. Lastres-Becker, R. de Miguel, F. Berrendero, J. A. Ramos, and J. Fernández-Ruiz, “The endogenous cannabinoid system and the basal ganglia: biochemical, pharmacological, and therapeutic aspects,” Pharmacology and Therapeutics, vol. 95, no. 2, pp. 137–152, 2002. View at Publisher · View at Google Scholar · View at Scopus
  153. P. Gubellini, B. Picconi, M. Bari et al., “Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission,” The Journal of Neuroscience, vol. 22, no. 16, pp. 6900–6907, 2002. View at Google Scholar · View at Scopus
  154. Y. Gilgun-Sherki, E. Melamed, R. Mechoulam, and D. Offen, “The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats,” Pharmacology and Toxicology, vol. 93, no. 2, pp. 66–70, 2003. View at Publisher · View at Google Scholar · View at Scopus
  155. D. T. Malone and D. A. Taylor, “Modulation by fluoxetine of striatal dopamine release following Δ9-tetrahydrocannabinol: a microdialysis study in conscious rats,” British Journal of Pharmacology, vol. 128, no. 1, pp. 21–26, 1999. View at Publisher · View at Google Scholar · View at Scopus
  156. G. Tanda, F. E. Pontieri, and G. Di Chiara, “Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ1 opioid receptor mechanism,” Science, vol. 276, no. 5321, pp. 2048–2050, 1997. View at Publisher · View at Google Scholar · View at Scopus
  157. R. G. Pertwee, A. Thomas, L. A. Stevenson et al., “The psychoactive plant cannabinoid, Δ 9- tetrahydrocannabinol, is antagonized by Δ 8- and Δ 9-tetrahydrocannabivarin in mice in vivo,” British Journal of Pharmacology, vol. 150, no. 5, pp. 586–594, 2007. View at Publisher · View at Google Scholar · View at Scopus
  158. A. Richter and W. Löscher, “(+)-WIN 55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters,” European Journal of Pharmacology, vol. 264, no. 3, pp. 371–377, 1994. View at Publisher · View at Google Scholar · View at Scopus
  159. Y. P. Maneuf, A. R. Crossman, and J. M. Brotchie, “The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease,” Experimental Neurology, vol. 148, no. 1, pp. 265–270, 1997. View at Publisher · View at Google Scholar
  160. G. Segovia, F. Mora, A. R. Crossman, and J. M. Brotchie, “Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease,” Movement Disorders, vol. 18, no. 2, pp. 138–149, 2003. View at Publisher · View at Google Scholar · View at Scopus
  161. M. G. Morgese, T. Cassano, V. Cuomo, and A. Giuffrida, “Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB1 and TRPV1 receptors,” Experimental Neurology, vol. 208, no. 1, pp. 110–119, 2007. View at Publisher · View at Google Scholar · View at Scopus
  162. M. G. Morgese, T. Cassano, S. Gaetani et al., “Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2,” Neurochemistry International, vol. 54, no. 1, pp. 56–64, 2009. View at Publisher · View at Google Scholar · View at Scopus
  163. B. Ferrer, N. Asbrock, S. Kathuria, D. Piomelli, and A. Giuffrida, “Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias,” European Journal of Neuroscience, vol. 18, no. 6, pp. 1607–1614, 2003. View at Publisher · View at Google Scholar · View at Scopus
  164. R. González-Aparicio and R. Moratalla, “Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson's disease,” Neurobiology of Disease, vol. 62, pp. 416–425, 2014. View at Publisher · View at Google Scholar · View at Scopus
  165. S. H. Fox, B. Henry, M. Hill, A. Crossman, and J. M. Brotchie, “Stimulation of Cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease,” Movement Disorders, vol. 17, no. 6, pp. 1180–1187, 2002. View at Publisher · View at Google Scholar · View at Scopus
  166. S. H. Fox, M. Kellett, A. P. Moore, A. R. Crossman, and J. M. Brotchie, “Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia,” Movement Disorders, vol. 17, no. 1, pp. 145–149, 2002. View at Publisher · View at Google Scholar · View at Scopus
  167. M. Solinas, Z. Justinova, S. R. Goldberg, and G. Tanda, “Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats,” Journal of Neurochemistry, vol. 98, no. 2, pp. 408–419, 2006. View at Publisher · View at Google Scholar · View at Scopus
  168. P. M. Zygmunt, J. Petersson, D. A. Andersson et al., “Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide,” Nature, vol. 400, no. 6743, pp. 452–457, 1999. View at Publisher · View at Google Scholar · View at Scopus
  169. D. Smart, M. J. Gunthorpe, J. C. Jerman et al., “The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1),” British Journal of Pharmacology, vol. 129, no. 2, pp. 227–230, 2000. View at Publisher · View at Google Scholar · View at Scopus
  170. V. Di Marzo, I. Lastres-Becker, T. Bisogno et al., “Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues,” European Journal of Pharmacology, vol. 420, no. 2-3, pp. 123–131, 2001. View at Publisher · View at Google Scholar · View at Scopus
  171. S. Marinelli, V. Di Marzo, N. Berretta et al., “Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors,” The Journal of Neuroscience, vol. 23, no. 8, pp. 3136–3144, 2003. View at Google Scholar · View at Scopus
  172. P. B. Smith, D. R. Compton, S. P. Welch, R. K. Razdan, R. Mechoulam, and B. R. Martin, “The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice,” Journal of Pharmacology and Experimental Therapeutics, vol. 270, no. 1, pp. 219–227, 1994. View at Google Scholar · View at Scopus
  173. E. Fride and R. Mechoulam, “Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent,” European Journal of Pharmacology, vol. 231, no. 2, pp. 313–314, 1993. View at Publisher · View at Google Scholar · View at Scopus
  174. E. De Lago, J. Fernández-Ruiz, S. Ortega-Gutiérrez, A. Viso, M. L. López-Rodríguez, and J. A. Ramos, “UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide,” European Journal of Pharmacology, vol. 449, no. 1-2, pp. 99–103, 2002. View at Publisher · View at Google Scholar · View at Scopus
  175. N. Ueda, R. A. Puffenbarger, S. Yamamoto, and D. G. Deutsch, “The fatty acid amide hydrolase (FAAH),” Chemistry and Physics of Lipids, vol. 108, no. 1-2, pp. 107–121, 2000. View at Publisher · View at Google Scholar · View at Scopus
  176. M. Maccarrone, “Fatty acid amide hydrolase: a potential target for next generation therapeutics,” Current Pharmaceutical Design, vol. 12, no. 6, pp. 759–772, 2006. View at Publisher · View at Google Scholar · View at Scopus
  177. V. Di Marzo and M. Maccarrone, “FAAH and anandamide: is 2-AG really the odd one out?” Trends in Pharmacological Sciences, vol. 29, no. 5, pp. 229–233, 2008. View at Publisher · View at Google Scholar · View at Scopus
  178. T. H. Johnston, P. Huot, S. H. Fox et al., “Fatty Acid Amide Hydrolase (FAAH) inhibition reduces L-3,4- dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-lesioned non-human primate model of Parkinson's disease,” Journal of Pharmacology and Experimental Therapeutics, vol. 336, no. 2, pp. 423–430, 2011. View at Publisher · View at Google Scholar · View at Scopus
  179. M. Celorrio, D. Fernández-Suáreza, E. Rojo-Bustamantea et al., “Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease,” Brain, Behavior, and Immunity, vol. 57, pp. 94–105, 2016. View at Publisher · View at Google Scholar
  180. M. Hodaie, J. S. Neimat, and A. M. Lozano, “The dopaminergic nigrostriatal system and Parkinson's disease: molecular events in development, disease, and cell death, and new therapeutic strategies,” Neurosurgery, vol. 60, no. 1, pp. 17–28, 2007. View at Publisher · View at Google Scholar · View at Scopus
  181. A. Sayd, M. Antón, F. Alén et al., “Systemic administration of oleoylethanolamide protects from neuroinflammation and anhedonia induced by LPS in rats,” International Journal of Neuropsychopharmacology, vol. 18, no. 6, pp. 1–14, 2015. View at Publisher · View at Google Scholar · View at Scopus
  182. I. Lastres-Becker, F. Molina-Holgado, J. A. Ramos, R. Mechoulam, and J. Fernández-Ruiz, “Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease,” Neurobiology of Disease, vol. 19, no. 1-2, pp. 96–107, 2005. View at Publisher · View at Google Scholar · View at Scopus
  183. S. V. More, H. Kumar, I. S. Kim, S.-Y. Song, and D.-K. Choi, “Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease,” Mediators of Inflammation, vol. 2013, Article ID 952375, 12 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  184. M. García-Arencibia, L. Ferraro, S. Tanganelli, and J. Fernández-Ruiz, “Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats,” Neuroscience Letters, vol. 438, no. 1, pp. 10–13, 2008. View at Publisher · View at Google Scholar · View at Scopus
  185. P. Huang, L.-Y. Liu-Chen, E. M. Unterwald, and A. Cowan, “Hyperlocomotion and paw tremors are two highly quantifiable signs of SR141716-precipitated withdrawal from delta9-tetrahydrocannabinol in C57BL/6 mice,” Neuroscience Letters, vol. 465, no. 1, pp. 66–70, 2009. View at Publisher · View at Google Scholar · View at Scopus
  186. S. González, C. Scorticati, M. García-Arencibia, R. de Miguel, J. A. Ramos, and J. Fernández-Ruiz, “Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease,” Brain Research, vol. 1073-1074, no. 1, pp. 209–219, 2006. View at Publisher · View at Google Scholar · View at Scopus
  187. E. Fernandez-Espejo, I. Caraballo, F. R. de Fonseca et al., “Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism,” Neurobiology of Disease, vol. 18, no. 3, pp. 591–601, 2005. View at Publisher · View at Google Scholar · View at Scopus
  188. F. El Banoua, I. Caraballo, J. A. Flores, B. Galan-Rodriguez, and E. Fernandez-Espejo, “Effects on turning of microinjections into basal ganglia of D1 and D2 dopamine receptors agonists and the cannabinoid CB1 antagonist SR141716A in a rat Parkinson's model,” Neurobiology of Disease, vol. 16, no. 2, pp. 377–385, 2004. View at Publisher · View at Google Scholar · View at Scopus
  189. X. Cao, L. Liang, J. R. Hadcock et al., “Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated rhesus monkeys,” Journal of Pharmacology and Experimental Therapeutics, vol. 323, no. 1, pp. 318–326, 2007. View at Publisher · View at Google Scholar · View at Scopus
  190. S. M. Papa, “The cannabinoid system in Parkinson's disease: multiple targets to motor effects,” Experimental Neurology, vol. 211, no. 2, pp. 334–338, 2008. View at Publisher · View at Google Scholar · View at Scopus
  191. M. García-Arencibia, S. González, E. de Lago, J. A. Ramos, R. Mechoulam, and J. Fernández-Ruiz, “Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties,” Brain Research, vol. 1134, no. 1, pp. 162–170, 2007. View at Publisher · View at Google Scholar · View at Scopus
  192. J. Fernández-Ruiz, M. Moreno-Martet, C. Rodríguez-Cueto et al., “Prospects for cannabinoid therapies in basal ganglia disorders,” British Journal of Pharmacology, vol. 163, no. 7, pp. 1365–1378, 2011. View at Publisher · View at Google Scholar · View at Scopus
  193. W. Gowers, A Manual of Diseases of the Nervous System, P. Blakiston's Son & Co, Philadelphia, Pa, USA, 1888.
  194. K. R. Müller-Vahl, “Treatment of Tourette syndrome with cannabinoids,” Behavioural Neurology, vol. 27, no. 1, pp. 119–124, 2013. View at Publisher · View at Google Scholar · View at Scopus
  195. K. R. Müller-Vahl, U. Schneider, H. Prevedel et al., “Δ9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial,” Journal of Clinical Psychiatry, vol. 64, no. 4, pp. 459–465, 2003. View at Publisher · View at Google Scholar · View at Scopus
  196. K. R. Müller-Vahl, U. Schneider, A. Koblenz et al., “Treatment of Tourette's syndrome with Δ9-tetrahydrocannabinol (THC): a randomized crossover trial,” Pharmacopsychiatry, vol. 35, no. 2, pp. 57–61, 2002. View at Publisher · View at Google Scholar · View at Scopus
  197. K. R. Muller-Vahl, H. Kolbe, U. Schneider, and H. M. Emrich, “Cannabis in movement disorders,” Forschende Komplementarmedizin, vol. 6, no. 3, pp. 23–27, 1999. View at Google Scholar · View at Scopus
  198. K. R. Müller-Vahl, U. Schneider, and H. M. Emrich, “Nabilone increases choreatic movements in Huntington's disease,” Movement Disorders, vol. 14, no. 6, pp. 1038–1040, 1999. View at Google Scholar · View at Scopus
  199. K. R. Müller-Vahl, H. Kolbe, U. Schneider, and H. M. Emrich, “Cannabinoids: possible role in patho-physiology and therapy of Gilles de la Tourette syndrome,” Acta Psychiatrica Scandinavica, vol. 98, no. 6, pp. 502–506, 1998. View at Publisher · View at Google Scholar · View at Scopus
  200. P. Consroe, R. Sandyk, and S. R. Snider, “Open label evaluation of cannabidiol in dystonic movement disorders,” International Journal of Neuroscience, vol. 30, no. 4, pp. 277–282, 1986. View at Publisher · View at Google Scholar · View at Scopus
  201. R. Sandyk, S. R. Snider, P. Consroe, and S. M. Elias, “Cannabidiol in dystonic movement disorders,” Psychiatry Research, vol. 18, no. 3, p. 291, 1986. View at Publisher · View at Google Scholar · View at Scopus
  202. K. Venderova, E. Ruzicka, V. Vorisek, and P. Visnovsky, “Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms,” Movement Disorders, vol. 19, no. 9, pp. 1102–1106, 2004. View at Publisher · View at Google Scholar
  203. I. Lotan, T. Treves, Y. Roditi, and R. Djaldetti, “Medical marijuana (cannabis) treatment for motor and non-motor symptoms in Parkinson's disease. An open-label observational study,” Movement Disorders, vol. 28, no. 1, p. 448, 2013. View at Google Scholar
  204. J. P. Frankel, A. Hughes, A. A. J. Lees, and G. M. Stern, “Marijuana for parkinsonian tremor,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 53, no. 5, p. 436, 1990. View at Google Scholar
  205. C. B. Carroll, P. G. Bain, L. Teare, X. Liu, C. Joint, and C. Wroath, “Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study,” Neurology, vol. 63, pp. 1245–1250, 2004. View at Google Scholar
  206. S. R. Snider and P. Consroe, “Beneficial and adverse effects of cannabidiol in a Parkinson patient with sinemet-induced dystonic dyskinesia,” Neurology, vol. 35, article 201, 1985. View at Google Scholar
  207. K. A. Sieradzan, S. H. Fox, J. Dick, and J. M. Brotchie, “The effects of the cannabinoid receptor agonist nabilone on L-DOPA induced dyskinesia in patients with idiopathic Parkinson's disease,” Movement Disorders, vol. 13, supplement 2, p. 29, 1998. View at Google Scholar
  208. K. A. Sieradzan, S. H. Fox, M. Hill, J. P. R. Dick, A. R. Crossman, and J. M. Brotchie, “Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: A Pilot Study,” Neurology, vol. 57, no. 11, pp. 2108–2111, 2001. View at Publisher · View at Google Scholar · View at Scopus
  209. P. Consroe, “Brain cannabinoid systems as targets for the therapy of neurological disorders,” Neurobiology of Disease, vol. 5, no. 6, pp. 534–551, 1998. View at Publisher · View at Google Scholar · View at Scopus
  210. V. Mesnage, J. L. Houeto, A. M. Bonnet et al., “Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease,” Clinical Neuropharmacology, vol. 27, no. 3, pp. 108–110, 2004. View at Publisher · View at Google Scholar · View at Scopus
  211. B. S. Koppel, J. C. M. Brust, T. Fife et al., “Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology,” Neurology, vol. 82, no. 17, pp. 1556–1563, 2014. View at Publisher · View at Google Scholar · View at Scopus
  212. A. Chatterjee, A. Almahrezi, M. Ware, and M. A. Fitzcharles, “A dramatic response to inhaled cannabis in a woman with central thalamic pain and dystonia,” Journal of Pain and Symptom Management, vol. 24, no. 1, pp. 4–6, 2002. View at Publisher · View at Google Scholar · View at Scopus
  213. C. D. Marsden, “Treatment of torsion dystonia,” in Disorders of Movement, Current Status of Modern Therapy, A. Barbeau, Ed., vol. 8, pp. 81–104, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 1981. View at Google Scholar
  214. M. C. Uribe Roca, F. Micheli, and R. Viotti, “Cannabis sativa and dystonia secondary to Wilson's disease,” Movement Disorders, vol. 20, no. 1, pp. 113–115, 2005. View at Publisher · View at Google Scholar · View at Scopus
  215. S. R. Snider and P. Consroe, “Treatment of Meige's syndrome with cannabidiol,” Neurology, vol. 34, article 147, 1984. View at Google Scholar
  216. R. Lorenz, “On the application of cannabis in paediatrics and epileptology,” Neuroendocrinology Letters, vol. 25, no. 1-2, pp. 40–44, 2004. View at Google Scholar
  217. A. Curtis, I. Mitchell, S. Patel, N. Ives, and H. Rickards, “A pilot study using nabilone for symptomatic treatment in Huntington's disease,” Movement Disorders, vol. 24, no. 15, pp. 2254–2259, 2009. View at Publisher · View at Google Scholar · View at Scopus
  218. M. J. Armstrong and J. M. Miyasaki, “Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology,” Neurology, vol. 79, no. 6, pp. 597–603, 2012. View at Publisher · View at Google Scholar · View at Scopus
  219. R. Sandyk, P. Consroe, L. Stern, S. R. Snider, and D. Bliklen, “Preliminary trial of cannabidiol in Huntington's disease,” in Marijuana: An International Research Report, G. Chesher, P. Consroe, and R. Musty, Eds., Australian Government Publishing Service, Canberra, Australia, 1988. View at Google Scholar
  220. P. Consroe, J. Laguna, J. Allender et al., “Controlled clinical trial of cannabidiol in Huntington's disease,” Pharmacology, Biochemistry and Behavior, vol. 40, no. 3, pp. 701–708, 1991. View at Publisher · View at Google Scholar · View at Scopus
  221. N. M. Kogan and R. Mechoulam, “Cannabinoids in health and disease,” Dialogues in Clinical Neuroscience, vol. 9, no. 4, pp. 413–430, 2007. View at Google Scholar · View at Scopus
  222. R. Sandyk and G. Awerbuch, “Marijuana and tourette’s syndrome,” Journal of Clinical Psychopharmacology, vol. 8, no. 6, pp. 444–445, 1988. View at Publisher · View at Google Scholar · View at Scopus
  223. M. Hemming and P. M. Yellowlees, “Effective treatment of Tourette's syndrome with marijuana,” Journal of Psychopharmacology, vol. 7, no. 4, pp. 389–391, 1993. View at Publisher · View at Google Scholar · View at Scopus
  224. A. Hasan, A. Rothenberger, A. Münchau, T. Wobrock, P. Falkai, and V. Roessner, “Oral Δ9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report,” Journal of Clinical Psychopharmacology, vol. 30, no. 2, pp. 190–192, 2010. View at Publisher · View at Google Scholar · View at Scopus
  225. A. Brunnauer, F. M. Segmiller, T. Volkamer, G. Laux, N. Müller, and S. Dehning, “Cannabinoids improve driving ability in a Tourette's patient,” Psychiatry Research, vol. 190, no. 2-3, p. 382, 2011. View at Publisher · View at Google Scholar · View at Scopus
  226. G. Berding, K. Müller-Vahl, U. Schneider et al., “[123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Δ9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in Tourette patients,” Biological Psychiatry, vol. 55, no. 9, pp. 904–915, 2004. View at Publisher · View at Google Scholar · View at Scopus
  227. J. Ševčík and K. Mašek, “Potential role of cannabinoids in Parkinson's disease,” Drugs and Aging, vol. 16, no. 6, pp. 391–395, 2000. View at Publisher · View at Google Scholar · View at Scopus
  228. H. Pan, P. Mukhopadhyay, M. Rajesh et al., “Cannabidiol attenuates cisplatin-Lnduced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death,” Journal of Pharmacology and Experimental Therapeutics, vol. 328, no. 3, pp. 708–714, 2009. View at Publisher · View at Google Scholar · View at Scopus
  229. M. S. Hernandes, C. C. Café-Mendes, and L. R. G. Britto, “NADPH oxidase and the degeneration of dopaminergic neurons in Parkinsonian mice,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 157857, 13 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  230. E. Hebert-Chatelain, L. Reguero, N. Puente et al., “Cannabinoid control of brain bioenergetics: exploring the subcellular localization of the CB1 receptor,” Molecular Metabolism, vol. 3, no. 4, pp. 495–504, 2014. View at Publisher · View at Google Scholar · View at Scopus
  231. S. Yamaori, J. Ebisawa, Y. Okushima, I. Yamamoto, and K. Watanabe, “Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety,” Life Sciences, vol. 88, no. 15-16, pp. 730–736, 2011. View at Publisher · View at Google Scholar · View at Scopus
  232. A. J. Hampson, M. Grimaldi, J. Axelrod, and D. Wink, “Cannabidiol and (−)Δ9-tetrahydrocannabinol are neuroprotective antioxidants,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 14, pp. 8268–8273, 1998. View at Publisher · View at Google Scholar · View at Scopus
  233. G. Bénard, F. Massa, N. Puente et al., “Mitochondrial CB1 receptors regulate neuronal energy metabolism,” Nature Neuroscience, vol. 15, no. 4, pp. 558–564, 2012. View at Publisher · View at Google Scholar
  234. S. Amor, F. Puentes, D. Baker, and P. Van Der Valk, “Inflammation in neurodegenerative diseases,” Immunology, vol. 129, no. 2, pp. 154–169, 2010. View at Publisher · View at Google Scholar · View at Scopus
  235. S. Amor, L. A. N. Peferoen, D. Y. S. Vogel et al., “Inflammation in neurodegenerative diseases—an update,” Immunology, vol. 142, no. 2, pp. 151–166, 2014. View at Publisher · View at Google Scholar · View at Scopus
  236. L. F. Clark and T. Kodadek, “The immune system and neuroinflammation as potential sources of blood-based biomarkers for Alzheimer’s disease, Parkinson’s disease, and huntington’s disease,” ACS Chemical Neuroscience, vol. 7, no. 5, pp. 520–527, 2016. View at Publisher · View at Google Scholar
  237. M. A. Mena and J. García De Yébenes, “Glial cells as players in parkinsonism: the ‘good,’ the ‘bad,’ and the ‘mysterious’ glia,” Neuroscientist, vol. 14, no. 6, pp. 544–560, 2008. View at Publisher · View at Google Scholar · View at Scopus
  238. P. L. McGeer and E. G. McGeer, “Glial reactions in Parkinson's disease,” Movement Disorders, vol. 23, no. 4, pp. 474–483, 2008. View at Publisher · View at Google Scholar · View at Scopus
  239. N. Stella, “Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas,” Glia, vol. 58, no. 9, pp. 1017–1030, 2010. View at Publisher · View at Google Scholar · View at Scopus
  240. A. Klegeris, C. J. Bissonnette, and P. L. McGeer, “Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor,” British Journal of Pharmacology, vol. 139, no. 4, pp. 775–786, 2003. View at Publisher · View at Google Scholar · View at Scopus
  241. G. Esposito, C. Scuderi, C. Savani et al., “Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression,” British Journal of Pharmacology, vol. 151, no. 8, pp. 1272–1279, 2007. View at Publisher · View at Google Scholar · View at Scopus
  242. B. Watzl, P. Scuderi, and R. R. Watson, “Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro,” Advances in Experimental Medicine and Biology, vol. 288, pp. 63–70, 1991. View at Publisher · View at Google Scholar · View at Scopus
  243. M. D. Srivastava, B. I. S. Srivastava, and B. Brouhard, “Δ9 Tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells,” Immunopharmacology, vol. 40, no. 3, pp. 179–185, 1998. View at Publisher · View at Google Scholar · View at Scopus
  244. A. M. Malfait, R. Gallily, P. F. Sumariwalla et al., “The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 17, pp. 9561–9566, 2000. View at Publisher · View at Google Scholar · View at Scopus
  245. R. Mechoulam, L. A. Parker, and R. Gallily, “Cannabidiol: an overview of some pharmacological aspects,” Journal of Clinical Pharmacology, vol. 42, no. 11, pp. 11S–19S, 2002. View at Google Scholar · View at Scopus
  246. R. Mechoulam, M. Peters, E. Murillo-Rodriguez, and L. O. Hanuš, “Cannabidiol—recent advances,” Chemistry and Biodiversity, vol. 4, no. 8, pp. 1678–1692, 2007. View at Publisher · View at Google Scholar · View at Scopus
  247. B. Costa, M. Colleoni, S. Conti et al., “Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 369, no. 3, pp. 294–299, 2004. View at Publisher · View at Google Scholar · View at Scopus
  248. B. Costa, A. E. Trovato, F. Comelli, G. Giagnoni, and M. Colleoni, “The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain,” European Journal of Pharmacology, vol. 556, no. 1–3, pp. 75–83, 2007. View at Publisher · View at Google Scholar · View at Scopus
  249. F. Assaf, M. Fishbein, M. Gafni, O. Keren, and Y. Sarne, “Pre- and post-conditioning treatment with an ultra-low dose of Δ9-tetrahydrocannabinol (THC) protects against pentylenetetrazole (PTZ)-induced cognitive damage,” Behavioural Brain Research, vol. 220, no. 1, pp. 194–201, 2011. View at Publisher · View at Google Scholar · View at Scopus
  250. P. E. Szmitko and S. Verma, “Does cannabis hold the key to treating cardiometabolic disease?” Nature Clinical Practice Cardiovascular Medicine, vol. 3, no. 3, pp. 116–117, 2006. View at Publisher · View at Google Scholar · View at Scopus
  251. M. Fishbein-Kaminietsky, M. Gafni, and Y. Sarne, “Ultralow doses of cannabinoid drugs protect the mouse brain from inflammation-induced cognitive damage,” Journal of Neuroscience Research, vol. 92, no. 12, pp. 1669–1677, 2014. View at Publisher · View at Google Scholar · View at Scopus
  252. O. Sagredo, M. García-Arencibia, E. de Lago, S. Finetti, A. Decio, and J. Fernández-Ruiz, “Cannabinoids and neuroprotection in basal ganglia disorders,” Molecular Neurobiology, vol. 36, no. 1, pp. 82–91, 2007. View at Publisher · View at Google Scholar · View at Scopus
  253. D. A. Price, A. A. Martinez, A. Seillier et al., “WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease,” European Journal of Neuroscience, vol. 29, no. 11, pp. 2177–2186, 2009. View at Publisher · View at Google Scholar · View at Scopus
  254. J. Martínez-Orgado, D. Fernández-López, I. Lizasoain, and J. Romero, “The seek of neuroprotection: introducing cannabinoids,” Recent Patents on CNS Drug Discovery, vol. 2, no. 2, pp. 131–139, 2007. View at Publisher · View at Google Scholar · View at Scopus
  255. J. Romero and J. Martínez-Orgado, “Cannabinoids and neurodegenerative diseases,” CNS and Neurological Disorders—Drug Targets, vol. 8, no. 6, pp. 440–450, 2009. View at Publisher · View at Google Scholar · View at Scopus
  256. M. F. Beal, “Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis,” Annals of Neurology, vol. 44, no. 3, pp. S110–S114, 1998. View at Publisher · View at Google Scholar · View at Scopus
  257. S. Valdeolivas, V. Satta, R. G. Pertwee, J. Fernández-Ruiz, and O. Sagredo, “Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors,” ACS Chemical Neuroscience, vol. 3, no. 5, pp. 400–406, 2012. View at Publisher · View at Google Scholar · View at Scopus
  258. M. Zeissler, C. Hanemann, J. Zajicek, and C. Carroll, “FAAH inhibition is protective in a cell culture model of Parkinson's disease,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 83, supplement 2, p. A15, 2012. View at Publisher · View at Google Scholar
  259. M. Sophie and B. Ford, “Management of pain in Parkinson's disease,” CNS Drugs, vol. 26, no. 11, pp. 937–948, 2012. View at Publisher · View at Google Scholar · View at Scopus
  260. E. G. Silva, M. A. Viana, and E. M. Quagliato, “Diagnostic of parkinsonian syndrome in a Brazilian movement disorders clinic,” Revista Neurociências, vol. 13, no. 4, pp. 173–177, 2005. View at Google Scholar
  261. M. Tinazzi, C. Del Vesco, E. Fincati et al., “Pain and motor complications in Parkinson's disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 77, no. 7, pp. 822–825, 2006. View at Publisher · View at Google Scholar · View at Scopus
  262. J. I. Sage, “Pain in Parkinson's disease,” Current Treatment Options in Neurology, vol. 6, no. 3, pp. 191–200, 2004. View at Publisher · View at Google Scholar · View at Scopus
  263. R. H. Dworkin, E. M. Nagasako, B. S. Galer, R. D. Hetzel, and J. T. Farrar, “Assessment of pain and pain-related quality of life in clinical trials,” in Handbook of Pain Assessment, D. C. Turk and R. Melzack, Eds., pp. 519–548, Guilford, New York, NY, USA, 2nd edition, 2001. View at Google Scholar
  264. R. H. Dworkin, M. Backonja, M. C. Rowbotham et al., “Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations,” Archives of Neurology, vol. 60, no. 11, pp. 1524–1534, 2003. View at Publisher · View at Google Scholar · View at Scopus
  265. R. H. Dworkin, A. E. Corbin, J. P. Young Jr. et al., “Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial,” Neurology, vol. 60, no. 8, pp. 1274–1283, 2003. View at Publisher · View at Google Scholar · View at Scopus
  266. L. Greenbaum, I. Tegeder, Y. Barhum, E. Melamed, Y. Roditi, and R. Djaldetti, “Contribution of genetic variants to pain susceptibility in Parkinson disease,” European Journal of Pain, vol. 16, no. 9, pp. 1243–1250, 2012. View at Publisher · View at Google Scholar · View at Scopus
  267. A. Calignano, G. La Rana, A. Giuffrida, and D. Piomelli, “Control of pain initiation by endogenous cannabinoids,” Nature, vol. 394, no. 6690, pp. 277–281, 1998. View at Publisher · View at Google Scholar · View at Scopus
  268. R. J. Ellis, W. Toperoff, F. Vaida et al., “Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial,” Neuropsychopharmacology, vol. 34, no. 3, pp. 672–680, 2009. View at Publisher · View at Google Scholar · View at Scopus
  269. B. Wilsey, T. Marcotte, A. Tsodikov et al., “A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain,” Journal of Pain, vol. 9, no. 6, pp. 506–521, 2008. View at Publisher · View at Google Scholar · View at Scopus
  270. D. I. Abrams, C. A. Jay, S. B. Shade et al., “Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial,” Neurology, vol. 68, no. 7, pp. 515–521, 2007. View at Publisher · View at Google Scholar · View at Scopus
  271. J. S. Berman, C. Symonds, and R. Birch, “Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial,” Pain, vol. 112, no. 3, pp. 299–306, 2004. View at Publisher · View at Google Scholar · View at Scopus
  272. K. B. Svendsen, T. S. Jensen, and F. W. Bach, “Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial,” British Medical Journal, vol. 329, no. 7460, pp. 253–257, 2004. View at Publisher · View at Google Scholar · View at Scopus
  273. D. J. Rog, T. J. Nurmikko, T. Friede, and C. A. Young, “Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis,” Neurology, vol. 65, no. 6, pp. 812–819, 2005. View at Publisher · View at Google Scholar · View at Scopus
  274. T. J. Nurmikko, M. G. Serpell, B. Hoggart, P. J. Toomey, B. J. Morlion, and D. Haines, “Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial,” Pain, vol. 133, no. 1–3, pp. 210–220, 2007. View at Publisher · View at Google Scholar · View at Scopus
  275. K. P. Hill, “Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review,” The Journal of the American Medical Association, vol. 313, no. 24, pp. 2474–2483, 2015. View at Publisher · View at Google Scholar · View at Scopus
  276. M. E. Lynch and F. Campbell, “Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials,” British Journal of Clinical Pharmacology, vol. 72, no. 5, pp. 735–744, 2011. View at Publisher · View at Google Scholar · View at Scopus
  277. M. I. Martín Fontelles and C. Goicoechea García, “Role of cannabinoids in the management of neuropathic pain,” CNS Drugs, vol. 22, no. 8, pp. 645–653, 2008. View at Publisher · View at Google Scholar · View at Scopus
  278. M. Iskedjian, B. Bereza, A. Gordon, C. Piwko, and T. R. Einarson, “Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain,” Current Medical Research and Opinion, vol. 23, no. 1, pp. 17–24, 2007. View at Publisher · View at Google Scholar · View at Scopus
  279. S. Corey, “Recent developments in the therapeutic potential of cannabinoids,” Puerto Rico Health Sciences Journal, vol. 24, no. 1, pp. 19–26, 2005. View at Google Scholar · View at Scopus
  280. P. F. Smith, “Cannabinoids in the treatment of pain and spasticity in multiple sclerosis,” Current Opinion in Investigational Drugs, vol. 3, no. 6, pp. 859–864, 2002. View at Google Scholar · View at Scopus
  281. F. A. Campbell, M. R. Tramèr, D. Carroll, D. J. M. Reynolds, R. A. Moore, and H. J. McQuay, “Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review,” British Medical Journal, vol. 323, no. 7303, pp. 13–16, 2001. View at Publisher · View at Google Scholar · View at Scopus
  282. W. J. G. Hoogendijk, I. E. C. Sommer, G. Tissingh, D. J. H. Deeg, and E. C. Wolters, “Depression in Parkinson's disease: the impact of symptom overlap on prevalence,” Psychosomatics, vol. 39, no. 5, pp. 416–421, 1998. View at Publisher · View at Google Scholar · View at Scopus
  283. M. Yamamoto, “Depression in Parkinson's disease: its prevalence, diagnosis, and neurochemical background,” Journal of Neurology, vol. 248, no. 3, pp. III5–11, 2001. View at Google Scholar
  284. J. S. A. M. Reijnders, U. Ehrt, W. E. J. Weber, D. Aarsland, and A. F. G. Leentjens, “A systematic review of prevalence studies of depression in Parkinson's disease,” Movement Disorders, vol. 23, no. 2, pp. 183–189, 2008. View at Publisher · View at Google Scholar · View at Scopus
  285. A. Schrag, A. Hovris, D. Morley, N. Quinn, and M. Jahanshahi, “Caregiver-burden in parkinson's disease is closely associated with psychiatric symptoms, falls, and disability,” Parkinsonism & Related Disorders, vol. 12, no. 1, pp. 35–41, 2006. View at Publisher · View at Google Scholar · View at Scopus
  286. A. Schrag, “Quality of life and depression in Parkinson's disease,” Journal of the Neurological Sciences, vol. 248, no. 1-2, pp. 151–157, 2006. View at Publisher · View at Google Scholar · View at Scopus
  287. H. Reichmann, C. Schneider, and M. Löhle, “Non-motor features of Parkinson's disease: depression and dementia,” Parkinsonism and Related Disorders, vol. 15, no. 3, pp. S87–S92, 2009. View at Publisher · View at Google Scholar · View at Scopus
  288. B. B. Gorzalka and M. N. Hill, “Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 35, no. 7, pp. 1575–1585, 2011. View at Publisher · View at Google Scholar · View at Scopus
  289. M. Navarro, E. Hernández, R. M. Muñoz et al., “Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat,” NeuroReport, vol. 8, no. 2, pp. 491–496, 1997. View at Publisher · View at Google Scholar · View at Scopus
  290. F. A. Moreira and B. Lutz, “The endocannabinoid system: emotion, learning and addiction,” Addiction Biology, vol. 13, no. 2, pp. 196–212, 2008. View at Publisher · View at Google Scholar · View at Scopus
  291. F. A. Moreira and J. A. S. Crippa, “The psychiatric side-effects of rimonabant,” Revista Brasileira de Psiquiatria, vol. 31, no. 2, pp. 145–153, 2009. View at Publisher · View at Google Scholar · View at Scopus
  292. F. J. Barrero, I. Ampuero, B. Morales et al., “Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1),” The Pharmacogenomics Journal, vol. 5, no. 2, pp. 135–141, 2005. View at Publisher · View at Google Scholar
  293. F. R. Bambico, P. R. Hattan, J. P. Garant, and G. Gobbi, “Effect of delta-9-tetrahydrocannabinol on behavioral despair and on pre- and postsynaptic serotonergic transmission,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 38, no. 1, pp. 88–96, 2012. View at Google Scholar
  294. G. Gobbi, F. R. Bambico, R. Mangieri et al., “Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 51, pp. 18620–18625, 2005. View at Publisher · View at Google Scholar · View at Scopus
  295. T. F. Denson and M. Earleywine, “Decreased depression in marijuana users,” Addictive Behaviors, vol. 31, no. 4, pp. 738–742, 2006. View at Publisher · View at Google Scholar · View at Scopus
  296. L. Degenhardt, W. Hall, and M. Lynskey, “Exploring the association between cannabis use and depression,” Addiction, vol. 98, no. 11, pp. 1493–1504, 2003. View at Publisher · View at Google Scholar · View at Scopus
  297. B. Porter, R. MacFarlane, and R. Walker, “The frequency and nature of sleep disorders in a community-based population of patients with Parkinson's disease,” European Journal of Neurology, vol. 15, no. 1, pp. 46–50, 2008. View at Publisher · View at Google Scholar · View at Scopus
  298. A. Videnovic and D. Golombek, “Circadian and sleep disorders in Parkinson's disease,” Experimental Neurology, vol. 243, pp. 45–56, 2013. View at Publisher · View at Google Scholar · View at Scopus
  299. L. M. Trotti and D. L. Bliwise, “Treatment of the sleep disorders associated with Parkinson's disease,” Neurotherapeutics, vol. 11, no. 1, pp. 68–77, 2014. View at Publisher · View at Google Scholar · View at Scopus
  300. M. Stacy, “Sleep disorders in Parkinson's disease: epidemiology and management,” Drugs and Aging, vol. 19, no. 10, pp. 733–739, 2002. View at Publisher · View at Google Scholar · View at Scopus
  301. E. B. Russo, G. W. Guy, and P. J. Robson, “Cannabis, pain, and sleep: lessons from therapeutic clinical trials of sativex, a cannabis-based medicine,” Chemistry & Biodiversity, vol. 4, no. 8, pp. 1729–1743, 2007. View at Google Scholar